| P50 | author | Werner Melzer | Q88705506 |
| | Bernhard Landwehrmeyer | Q42047023 |
| P2093 | author name string | Katrin S Lindenberg | |
| | Zoita Andronache | |
| | Peter Braubach | |
| | Murat Orynbayev | |
| | Tanja Hering | |
| P2860 | cites work | Malignant hyperthermia | Q21203008 |
| | A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter | Q24306850 |
| | Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1 | Q24310249 |
| | Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series | Q24537164 |
| | Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model | Q24647950 |
| | Inhibitory control over Ca(2+) sparks via mechanosensitive channels is disrupted in dystrophin deficient muscle but restored by mini-dystrophin expression | Q27438151 |
| | The hunt for huntingtin function: interaction partners tell many different stories | Q28203006 |
| | Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases | Q28269333 |
| | Normal huntingtin function: an alternative approach to Huntington's disease | Q28281904 |
| | Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form | Q28509836 |
| | Calsequestrin content and SERCA determine normal and maximal Ca2+ storage levels in sarcoplasmic reticulum of fast- and slow-twitch fibres of rat | Q28572127 |
| | HAP1 facilitates effects of mutant huntingtin on inositol 1,4,5-trisphosphate-induced Ca release in primary culture of striatal medium spiny neurons | Q28592352 |
| | Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice | Q29615357 |
| | Calcium, ATP, and ROS: a mitochondrial love-hate triangle | Q29619742 |
| | Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression | Q33291754 |
| | Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease | Q33517121 |
| | Characterization and temporal development of cores in a mouse model of malignant hyperthermia | Q33564704 |
| | Mitochondrial matters of the brain: the role in Huntington's disease | Q33580327 |
| | Hyperactive intracellular calcium signaling associated with localized mitochondrial defects in skeletal muscle of an animal model of amyotrophic lateral sclerosis | Q33581470 |
| | Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. | Q33850154 |
| | Cysteine-3635 is responsible for skeletal muscle ryanodine receptor modulation by NO | Q33944345 |
| | Dantrolene--a review of its pharmacology, therapeutic use and new developments | Q33976686 |
| | Ryanodine receptors: structure, expression, molecular details, and function in calcium release. | Q34024377 |
| | Mitochondrial calcium uptake capacity as a therapeutic target in the R6/2 mouse model of Huntington's disease | Q34046887 |
| | The time-course of Ca2+ exchange with calmodulin, troponin, parvalbumin, and myosin in response to transient increases in Ca2+ | Q34252245 |
| | A general procedure for determining the rate of calcium release from the sarcoplasmic reticulum in skeletal muscle fibers | Q34259446 |
| | Myoplasmic binding of fura-2 investigated by steady-state fluorescence and absorbance measurements | Q34260981 |
| | S100A1 promotes action potential-initiated calcium release flux and force production in skeletal muscle | Q34304947 |
| | In vitro motility assay of atrial and ventricular myosin from pig. | Q34442087 |
| | Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli | Q34605764 |
| | Polyglutamine diseases: emerging concepts in pathogenesis and therapy | Q34696955 |
| | Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington's disease | Q34838143 |
| | Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders | Q34952853 |
| | Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias | Q34981549 |
| | Mitochondrial calcium uptake regulates rapid calcium transients in skeletal muscle during excitation-contraction (E-C) coupling | Q35213316 |
| | Rate and correlates of weight change in Huntington's disease | Q35479351 |
| | Dantrolene is neuroprotective in Huntington's disease transgenic mouse model | Q35605391 |
| | Intracellular calcium movements during excitation-contraction coupling in mammalian slow-twitch and fast-twitch muscle fibers | Q35860155 |
| | Deranged neuronal calcium signaling and Huntington disease. | Q35874324 |
| | The molecular basis of skeletal muscle atrophy | Q35882113 |
| | Cleavage pattern and emerging asymmetry of the mouse embryo. | Q36337947 |
| | Sarcoplasmic reticulum: the dynamic calcium governor of muscle | Q36396221 |
| | Perchlorate enhances transmission in skeletal muscle excitation-contraction coupling | Q36435131 |
| | Effects of dantrolene on steps of excitation-contraction coupling in mammalian skeletal muscle fibers. | Q36444775 |
| | Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease | Q36579470 |
| | Unloaded speed of shortening in voltage-clamped intact skeletal muscle fibers from wt, mdx, and transgenic minidystrophin mice using a novel high-speed acquisition system. | Q36678229 |
| | The corticostriatal pathway in Huntington's disease | Q36684263 |
| | N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease | Q36692396 |
| | The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis | Q36733673 |
| | Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases | Q36736582 |
| | The mitochondrial calcium uniporter (MCU): molecular identity and physiological roles | Q36760398 |
| | Major contribution of sarcoplasmic reticulum Ca(2+) depletion during long-lasting activation of skeletal muscle | Q36804627 |
| | Murine models of atrophy, cachexia, and sarcopenia in skeletal muscle | Q36941459 |
| | Interactions between sarco-endoplasmic reticulum and mitochondria in cardiac and skeletal muscle - pivotal roles in Ca²⁺ and reactive oxygen species signaling | Q37011991 |
| | Inositol 1,4,5-tripshosphate receptor, calcium signalling and Huntington's disease. | Q37056439 |
| | A retrograde signal from RyR1 alters DHP receptor inactivation and limits window Ca2+ release in muscle fibers of Y522S RyR1 knock-in mice | Q37132911 |
| | Impaired regulation of brain mitochondria by extramitochondrial Ca2+ in transgenic Huntington disease rats | Q37142702 |
| | Huntington's disease: from pathology and genetics to potential therapies | Q37157909 |
| | Mutant huntingtin and mitochondrial dysfunction | Q37308357 |
| | Impaired PGC-1alpha function in muscle in Huntington's disease. | Q37323316 |
| | Huntingtin as an essential integrator of intracellular vesicular trafficking | Q37408730 |
| | Mitochondrial death effectors: relevance to sarcopenia and disuse muscle atrophy. | Q37486939 |
| | Huntington's disease: the current state of research with peripheral tissues. | Q37491501 |
| | Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin | Q45297269 |
| | Formation of polyglutamine inclusions in non-CNS tissue | Q45298039 |
| | Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease | Q45298474 |
| | Low stability of Huntington muscle mitochondria against Ca2+ in R6/2 mice | Q45299927 |
| | Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy | Q45300771 |
| | Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects | Q45301339 |
| | Myopathy as a first symptom of Huntington's disease in a Marathon runner | Q45305237 |
| | Clinical correlates of mitochondrial function in Huntington's disease muscle | Q45305337 |
| | Weight loss in early stage of Huntington's disease | Q45307146 |
| | Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. | Q45307199 |
| | Ca2+-dependent proteolysis of junctophilin-1 and junctophilin-2 in skeletal and cardiac muscle | Q46308630 |
| | Comparison of the myoplasmic calcium transient elicited by an action potential in intact fibres of mdx and normal mice | Q46388856 |
| | Fura-2 calcium signals in skeletal muscle fibres loaded with high concentrations of EGTA. | Q49101093 |
| | SkM2, a Na+ channel cDNA clone from denervated skeletal muscle, encodes a tetrodotoxin-insensitive Na+ channel | Q50799937 |
| | Direct correlation of parvalbumin levels with myosin isoforms and succinate dehydrogenase activity on frozen sections of rodent muscle | Q52237716 |
| | Expression of myosin heavy chain isoforms in skeletal muscle of patients with peripheral arterial occlusive disease. | Q54059647 |
| | Fiber types in canine muscles: myosin isoform expression and functional characterization. | Q54560520 |
| | Caloric restriction prevents age-related decline in skeletal muscle dihydropyridine receptor and ryanodine receptor expression. | Q55067959 |
| | The removal of myoplasmic free calcium following calcium release in frog skeletal muscle | Q68800501 |
| | Depletion of calcium from the sarcoplasmic reticulum during calcium release in frog skeletal muscle | Q69023876 |
| | Age-related abnormalities in regulation of the ryanodine receptor in rat fast-twitch muscle | Q71129216 |
| | Hydrogen Peroxide Stimulates the Ca2+ Release Channel from Skeletal Muscle Sarcoplasmic Reticulum | Q71823683 |
| | Peroxynitrite modification of protein thiols: oxidation, nitrosylation, and S-glutathiolation of functionally important cysteine residue(s) in the sarcoplasmic reticulum Ca-ATPase | Q73011052 |
| | Calcium transients and calcium homeostasis in adult mouse fast-twitch skeletal muscle fibers in culture | Q73519613 |
| | Sarcoplasmic reticulum calcium release compared in slow-twitch and fast-twitch fibres of mouse muscle | Q73543667 |
| | Energetic depression caused by mitochondrial dysfunction | Q76377719 |
| | Oxidative damage to sarcoplasmic reticulum Ca2+-ATPase AT submicromolar iron concentrations: evidence for metal-catalyzed oxidation | Q77313314 |
| | Matching of sarcoplasmic reticulum and contractile properties in rat fast- and slow-twitch muscle fibres | Q79764982 |
| | Myosin - still a good reference for skeletal muscle fibre classification? | Q82383342 |
| | Increases in nuclear p65 activation in dystrophic skeletal muscle are secondary to increases in the cellular expression of p65 and are not solely produced by increases in IkappaB-alpha kinase activity | Q84290371 |
| | Ageing, but not yet senescent, rats exhibit reduced muscle quality and sarcoplasmic reticulum function | Q85100912 |
| | Novel excitation-contraction coupling related genes reveal aspects of muscle weakness beyond atrophy-new hopes for treatment of musculoskeletal diseases | Q37589556 |
| | Single muscle fiber properties in aging and disuse. | Q37618321 |
| | Molecular Mechanisms and Treatment Options for Muscle Wasting Diseases | Q37799373 |
| | Energy deficit in Huntington disease: why it matters | Q37834195 |
| | Expression and regulation of excitation-contraction coupling proteins in aging skeletal muscle | Q37870219 |
| | Fiber types in mammalian skeletal muscles | Q37947567 |
| | Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium | Q38603960 |
| | Numerical methods to determine calcium release flux from calcium transients in muscle cells | Q40118073 |
| | Skeletal muscle fibers: Inactivated or depleted after long depolarizations? | Q40226755 |
| | Voltage-activated calcium signals in myotubes loaded with high concentrations of EGTA. | Q40229264 |
| | Voltage-controlled Ca2+ release and entry flux in isolated adult muscle fibres of the mouse. | Q40470361 |
| | Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release | Q40551652 |
| | Voltage-dependent Ca2+ fluxes in skeletal myotubes determined using a removal model analysis | Q40607291 |
| | Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. | Q40721588 |
| | Mammalian skeletal muscle fiber type transitions | Q41322798 |
| | Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues | Q42503942 |
| | Calcium leak through ryanodine receptor is involved in neuronal death induced by mutant huntingtin | Q42515565 |
| | Widespread expression of Huntington's disease gene (IT15) protein product | Q42684112 |
| | RyR1 S-nitrosylation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice | Q43204679 |
| | Altered myoplasmic Ca(2+) handling in rat fast-twitch skeletal muscle fibres during disuse atrophy. | Q43226866 |
| | Myosin heavy chain isoform composition and Ca(2+) transients in fibres from enzymatically dissociated murine soleus and extensor digitorum longus muscles | Q43250079 |
| | NMDA receptor function in mouse models of Huntington disease | Q43825271 |
| | Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain | Q44092333 |
| | Inclusion formation in Huntington's disease R6/2 mouse muscle cultures | Q44581750 |
| | Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease | Q44806645 |
| | Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation | Q45173078 |
| | Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease | Q45259959 |
| | Intracellular Ca2+ signaling and human disease: the hunt begins with Huntington's. | Q45289606 |
| | Use of hand-held dynamometry in the evaluation of lower limb muscle strength in people with Huntington's disease | Q45291515 |
| | In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. | Q45293042 |
| | Complex I defect in muscle from patients with Huntington's disease. | Q45295738 |
| | Gene expression in Huntington's disease skeletal muscle: a potential biomarker | Q45296851 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| | ImageQuant | Q112270642 |
| P433 | issue | 5 | |
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 393-413 | |
| P577 | publication date | 2014-11-01 | |
| P1433 | published in | The Journal of General Physiology | Q1092259 |
| P1476 | title | Altered Ca(2+) signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntington's disease | |
| P478 | volume | 144 | |